RetroVirox Inc.

RetroVirox Inc. is a privately-held CRO exclusively focused on the virology field. RetroVirox offers a broad menu of antiviral and neutralization assays in a fee-for-service or F.T.E. pricing modality. Tests routinely performed in their laboratories include in vitro infectivity, replication, and neutralization assays to determine the antiviral activity of experimental drugs, and to evaluate candidate vaccines and antibodies. Assays against over a dozen different viruses have been validated and are offered to customers. Customized assays are also available upon request. Since its inception in 2008, RetroVirox has supported the preclinical discovery needs of hundreds of companies working in the virology field across more than 20 countries in five continents. Their customers include small start-ups, Biotechs, and large Pharmaceuticals. The company's headquarters is located in San Diego, California. Their last investment of $3.00M was a grant investment by the National Institutes of Health on 12 March 2015. Overall, RetroVirox Inc. serves a crucial role in the biotechnology and healthcare sectors, particularly in the virology field, offering comprehensive antiviral services to companies globally.